Bispecific antibodies as monotherapy or in combinations for non-hodgkin B-cell lymphoma: latest updates from the American society of hematology 2022 annual meeting

Bispecific antibodies as monotherapy or in combinations for non-hodgkin B-cell lymphoma: latest updates from the American society of hematology 2022 annual meeting

Abstract Recent evidence suggests that bispecific antibodies (BsAbs) exhibit promising efficacy and low toxicity even in heavily treated non-Hodgkin B-cell lymphoma (B-NHL). However, the role of BsAbs in previously untreated NHL and the efficacy and safety of BsAbs used in combination remain uncerta...

Full description

Bibliographic Details
Main Authors: Zhijuan Lin, Long Liu, Zhifeng Li, Bing Xu
Format: Article
Language:English
Published: BMC 2023-04-01
Series:Experimental Hematology & Oncology
Subjects:
Bispecific antibodies
Follicular lymphoma
Diffuse large B-cell lymphoma
Online Access:https://doi.org/10.1186/s40164-023-00404-3

Internet

https://doi.org/10.1186/s40164-023-00404-3

Similar Items